Senores Pharmaceuticals Ltd.
NSE: SENORES
Prev Close
799.7
Open Price
810
Volume
1,818
Today Low / High
810 / 815.05
52 WK Low / High
435.25 / 848.5
Range
773 - 854
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 813.5, with a change of 13.8 (1.72565%). The expected target range on the NSE is between 773 - 854. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
Senores Pharmaceuticals Ltd. Graph
Senores Pharmaceuticals Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Senores Pharmaceuticals Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 813.50, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 813.50 | 821.64 | 739.47 - 903.80 |
| 829.77 | 663.82 - 995.72 | ||
| 837.91 | 586.53 - 1,089.28 | ||
| Bearish Scenario | 813.50 | 805.37 | 724.83 - 885.90 |
| 797.23 | 637.78 - 956.68 | ||
| 789.10 | 552.37 - 1,025.82 |
Overview of Senores Pharmaceuticals Ltd.
ISIN
INE0RB801010
Industry
Drug Manufacturers - General
Vol.Avg
314,837
Market Cap
37,579,727,808
Last Dividend
0
Official Website
IPO Date
2024-12-30
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial income report data available. | |||||||||||
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial balance sheet data available. | ||||||||||||
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial cash flow statement data available. | |||||||||||
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 153.36 Cr | 57.08 Cr | 96.28 Cr | 0.6278 | 41.41 Cr | 32.38 Cr | 6.54 | 54.92 Cr | 0.2111 |
| 2025-06-30 | 130.30 Cr | 61.36 Cr | 68.94 Cr | 0.5291 | 28.18 Cr | 19.73 Cr | 4.60 | 37.52 Cr | 0.1514 |
| 2025-03-31 | 98.76 Cr | 66.52 Cr | 32.24 Cr | 0.3264 | 14.16 Cr | 17.83 Cr | 0.00 | 30.03 Cr | 0.1805 |
| 2024-12-31 | 103.02 Cr | 40.70 Cr | 62.32 Cr | 0.6049 | 21.48 Cr | 17.18 Cr | 5.04 | 30.84 Cr | 0.1668 |
| 2024-09-30 | 98.26 Cr | 47.92 Cr | 50.34 Cr | 0.5123 | 19.38 Cr | 12.84 Cr | 2.79 | 25.11 Cr | 0.1307 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial balance sheet data available. | |||||||||
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - General
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Cipla Limited | CIPLA | ₹1,515.60 | ₹1,224,248,826,481.00 | ₹10.00 |
| Abbott India Limited | ABBOTINDIA | ₹28,100.00 | ₹597,105,386,200.00 | ₹3,746.00 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | ₹2,540.50 | ₹430,376,029,377.00 | ₹123.00 |
| Gland Pharma Limited | GLAND | ₹1,680.30 | ₹276,840,217,567.00 | ₹59.00 |
| Pfizer Limited | PFIZER | ₹5,083.30 | ₹232,549,446,076.00 | ₹19,035.00 |
| Sanofi Consumer Healthcare India Ltd. | SANOFICONR | ₹4,617.60 | ₹106,346,200,147.00 | ₹3,703.00 |
| Sanofi India Limited | SANOFI | ₹4,087.00 | ₹94,126,152,114.00 | ₹15,179.00 |
| Marksans Pharma Limited | MARKSANS | ₹184.61 | ₹83,658,559,149.00 | ₹7,966.00 |
| Senores Pharmaceuticals Ltd. | SENORES | ₹813.50 | ₹37,464,593,838.00 | ₹1,818.00 |
Key Executives
Gender: male
Year Born: 1966
Gender: male
Year Born:
Gender: male
Year Born: 1963
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1985
Gender: male
Year Born:
FAQs about Senores Pharmaceuticals Ltd.
The CEO is Swapnil Jatinbhai Shah.
The current price is ₹816.00.
The range is ₹435.25-848.5.
The market capitalization is ₹3,757.97 crores.
The P/E ratio is 46.37.
The company operates in the Healthcare sector.
Overview of Senores Pharmaceuticals Ltd. (ISIN: INE0RB801010) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹3,757.97 crores and an average daily volume of 314,837 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹0.